[276 Pages Report] The global pneumonia diagnostics market is expected to enjoy a valuation of US$ 521.1 Million by the end of 2022, and further expand at a CAGR of 5.6% from 2022 to 2032, reaching a valuation of US$ 899.4 Million by 2032. The rising prevalence of pneumonia along with the growing need for early detection of this medical condition for initiating a proper treatment is a key factor driving demand for pneumonia diagnostics in the market.
Based on product, the streptococcus-based segment dominated the global pneumonia diagnostics market with a share of about 36.2% in 2021 and the trend is likely to continue during the assessment period. The overall pneumonia diagnostics market constituted approximately 0.6% of the global in vitro diagnostics market which stood at US$ 76.3 Billion in 2021.
| Attribute | Key Insights |
|---|---|
| Pneumonia Diagnostics Market Base Value (2021) | US$ 492.2 Million |
| Estimated Market Value (2022) | US$ 521.1 Million |
| Projected Market Value (2032) | US$ 899.4 Million |
| Value-based CAGR (2022 to 2032) | 5.6% |
| Market Share of Top 5 Countries | 43.9% |
Pneumonia continues to be a worldwide health concern with a high morbidity and fatality rate. Identifying the microbial pathogens that cause lung infection is crucial for optimal clinical care of pneumonia patients and is a significant barrier to conventional microbiological approaches.
In recent years, the discovery and deployment of molecular diagnostic assays for pneumonia have resulted in a significant improvement in the microbiological detection of respiratory pathogens. However, with new information about the microbiome and lungs presenting a dynamic microbiological ecosystem, our present notion of pneumonia is no longer completely practical, because this new idea of pneumonia entails modification of the lung microbiome.
Pneumonia diagnostics refers to solutions used to identify and detect pneumonia-causing agents like streptococcus, legionella, chlamydophilla, mycoplasma, etc. They are being increasingly utilized to detect pneumonia, especially during its early stages, to initiate a proper treatment approach.
Growing focus on reducing the mortality rate of pneumonia will therefore continue to boost the global pneumonia diagnostics market during the forecast period.
Similarly, increasing health awareness and availability of advanced diagnostic products will further accelerate growth in the market during the assessment period.
Regionally, North America held the highest market share of 30.6% in 2021 and it is likely to retain its dominance during the forecast period. Factors such as the increasing incidence of infectious diseases, the presence of leading manufacturers, and the availability of advanced products are propelling sales in the USA market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The overall sales in the pneumonia diagnostics market are projected to grow at 5.6% CAGR between 2022 and 2032, in comparison to the 4.5% CAGR registered from 2012 to 2021.
The rising incidence of pneumonia, the growing focus on early detection of infectious diseases, and advancements in diagnostics techniques are some of the key factors driving the global pneumonia diagnostic market.
Lung infections and other infectious diseases are becoming more common, there is an increase in the demand for diagnostics for pneumonia. One type of acute lung infection is pneumonia. A healthy person's lungs are made up of tiny sacs called alveoli that are filled with air as they breathe. Pneumonia causes the alveoli to bloat up with pus and fluid, which makes breathing challenging and limits oxygen intake.
The most common infectious cause of death in children worldwide is pneumonia. According to the World Health Organization 2021, pneumonia caused 740 to 180 deaths below the age of five in 2019, contributing to 14% of all deaths in children under the age of five but 22% of all deaths in children aged 1 to 5. Pneumonia affects children and families worldwide, although mortality is highest in Sub-Saharan Africa and South Asia.
The increasing adoption of point-of-care diagnostics and development in the detection of nucleic acid around the globe are set to boost the market in the given forecast period.
These factors, combined with the growing tendency toward preventive care are projected to increase the demand for pneumonia diagnostics products over the forecast period.
Rising Government Initiatives and Advancements in Diagnostic Technologies to Boost Market Over the Next Decade
The global pneumonia diagnostics market is likely to witness healthy growth owing to the increasing investments and initiatives by governments in emerging countries to modernize healthcare infrastructure.
The broad availability of rapid molecular diagnostic testing offers an unprecedented insight into pneumonia etiologies, challenging paradigms established by previous investigations from microbiological cultures.
Microscopy and culture of blood cultures, respiratory tract specimens, detection of antigens in urine and respiratory specimens, and detection of specific antibodies in the blood continue to be used in the routine laboratory evaluation of patients with pneumonia (serology). Nucleic acid detection technologies, such as polymerase chain reaction (PCR), have been available for more than two decades and are now commonplace in tertiary-level diagnostic laboratories.
Advancements in current diagnostics and innovation will thrive in the market in near future. For instance, Massachusetts Institute of Technology researchers have developed a sensor that can differentiate between viral and bacterial pneumonia infections, which they hope may aid doctors in selecting the best therapy.
Principal Consultant
The pricing pressure due to competition and difficulty in diagnosing can hamper the growth of the pneumonia diagnostics market during the forecast period.
In the community environment, the diagnosis and management of pneumonia usually become extremely complex. Physician approaches are primarily dependent on diagnosis information. In some circumstances, false positive results result in catastrophic patient mismanagement with antibiotics, as well as the possibility of superinfection and medication complications.
Immunoassay approaches for diagnosis are promising, however, they are still insufficient to screen for a wide range of pathogens. All these factors act as restraints in the growth of the pneumonia diagnostics market.
Similarly, low healthcare awareness across lower economies along with inadequate reimbursement policies is emerging as a significant impediment to the development of the pneumonia diagnostics market.
Increasing Incidence of Pneumonia and High Diagnostic Rates Driving Market in the USA
The USA dominated the North American pneumonia diagnostics market with a total market share of about 84.0% in 2021 and it is likely to expand at a steady pace during the forecast period.
Growth in the USA pneumonia diagnostics market is driven by the rising prevalence of pneumonia, increasing diagnostic screening rates due to high levels of awareness among people, and the presence of leading manufacturers.
Over the years, there has been a significant rise in the cases of pneumonia and pneumonia-related deaths across the USA which has necessitated the adoption of pneumonia diagnostics.
For instance, as per the Centers for Disease Control and Prevention (CDC), around 25.5% of USA adults suffered from pneumonia in 2020 while the total number of pneumonia-related deaths reached 47,601. In order to tackle this, people opt for various diagnostic tests and treatments. This will continue to boost the pneumonia diagnostics market in the country during the next ten years.
Similarly, increasing healthcare care spending and the presence of favourable reimbursement policies will further boost the demand for pneumonia diagnostic products in the USA market over the assessment period.
Easy Availability of Pneumonia Diagnostics Products Fuelling Sales in Canada
Canada held approximately 16.0% share in the North American pneumonia diagnostics market in 2021 and it is projected to display a growth rate of around 6.3% CAGR during the forecast period.
Growth in Canada’s pneumonia diagnostics market is projected to be driven by increasing production of pneumonia diagnostics products by top players, surging cases of pneumonia infection, and rising health awareness among people.
Favourable government support and the availability of better treatment approaches will further boost the market in the country over the next decade.
Continuous Advancements in Diagnostics Technologies to Boost Market in Germany
As per FMI, the overall pneumonia diagnostics market in Germany is set to exhibit a CAGR of nearly 7.5% during the forecast period (2022 to 2032). Germany is becoming increasingly popular when it comes to health and innovation.
With the increasing prevalence of chronic diseases and rising geriatric population demand for pneumonia diagnostics products will grow at a robust pace across Germany during the forecast period.
Similarly, the flourishing medical tourism sector and advancements in diagnostic technology will bode well for Germany’s pneumonia diagnostics market over the next ten years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand to Remain High for Streptococcus-Based Diagnostic Products
As per FMI, the streptococcus-based diagnostic products segment held the largest market share of about 36.2% in 2021 and it is expected to grow at a CAGR of 5.6% throughout the forecast period. This can be attributed to the rising prevalence of pneumococcal diseases and the increasing usage of streptococci-based diagnostic products for detecting this disease.
Streptococci are typically cultured on blood-supplemented agar media. This approach detects haemolysis, which is necessary for further identification procedures, and increases streptococci growth by introducing an external supply of catalase. Since this strain is the most common cause of pneumonia, this segment is set to drive the growth of the overall market.
With several competitors in the pneumonia diagnostics production sphere, the overall market is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.
Instances of key developmental strategies by the industry players in the pneumonia diagnostics market are given below:
| Attribute | Details |
|---|---|
| Estimated Market Size (2022) | US$ 521.1 Million |
| Projected Market Size (2032) | US$ 899.4 Million |
| Anticipated Growth Rate (2022 to 2032) | 5.6% |
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Japan, China, South Korea, Australia, New Zealand, Israel, Turkey, GCC Countries, and South Africa |
| Key Market Segments Covered | Product and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The global pneumonia diagnostics market size reached US$ 492.2 Million in 2021 and is likely to touch a valuation of US$ 521.1 Million in 2022.
The pneumonia diagnostics market is expected to reach US$ 899.4 Million by the end of 2032, with sales revenue expected to grow at 5.6% CAGR throughout the forecast period.
Growing adoption by the increasing geriatric population, innovative product development, and increasing prevalence of infectious diseases are some of the key trends in this market.
The USA, Canada, China, Germany, and the UK are driving demand for pneumonia diagnostics products.
The USA accounted for about 84.0% of the North American pneumonia diagnostics market in 2021.
Demand for pneumonia diagnostics in Europe is expected to grow at 7.5% CAGR over the next ten years.
The USA, China, and Germany are the key producers of pneumonia diagnostics.
Thermo Fisher Scientific Inc., Alere Inc., Quidel Corporation, Becton, Dickinson and Company, Meridian Bioscience, Inc, Qiagen N.V., bioMérieux SA, Bio-Rad Laboratories Inc., Cardinal Health Inc., Beckman Coulter Inc (Danaher Corporation), Hologic Inc., La Roche Ltd., Abbot Laboratories, Quest Diagnostics, and Luminex Corporation are some of the key players in the pneumonia diagnostics industry.
The pneumonia diagnostics market in Japan is set to expand at a CAGR of 5.5% during the forecast years.
The overall pneumonia diagnostics market in China is set to expand at a CAGR of 6.4% during the forecast period.
1. Executive Summary | Pneumonia Diagnostics Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Respiratory Disease Epidemiology 4.2. Product Adoption /Usage Analysis 4.3. Value Chain Analysis 4.4. Key Promotional Strategies, By Manufacturers 4.5. Regulatory Scenario 4.6. Porter’s Analysis 4.7. PESTLE Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare GDP Growth Outlook 5.1.3. Global In Vitro Diagnostics Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Historical Growth of Key Players 5.2.2. Cost of Product 5.2.3. Product Launches 5.2.4. Research and Development Expenditure by Key Players 5.2.5. Technological Advancements 5.2.6. Product Adoption Rate 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Product, 6.1.2. Revenue By Region 6.2. 2021 Market Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Product 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Product, 2012 to 2021 8.3. Current and Future Market Size (US$ Million) and Analysis and Forecast By Product, 2022 to 2032 8.3.1. Streptococcus based 8.3.2. Legionella based 8.3.3. Chlamydophilla based 8.3.4. Mycoplasma Pneumonia based 8.3.5. Viral Pneumonia based 8.4. Market Attractiveness Analysis By Product 9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region 9.1. Introduction 9.2. Pricing Analysis 9.3. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021 9.4. Current and Future Market Size (US$ Million) and Analysis and Forecast By Region, 2022 to 2032 9.4.1. North America 9.4.2. Latin America 9.4.3. Europe 9.4.4. East Asia 9.4.5. South Asia 9.4.6. Oceania 9.4.7. Middle East and Africa (MEA) 9.5. Market Attractiveness Analysis By Region 10. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 10.1. Introduction 10.2. Pricing Analysis 10.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 10.4. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 10.4.1. By Country 10.4.1.1. United States of America 10.4.1.2. Canada 10.4.2. By Product 10.5. Market Attractiveness Analysis 10.5.1. By Country 10.5.2. By Product 10.6. Market Trends 10.7. Key Market Participants - Intensity Mapping 10.8. Drivers and Restraints - Impact Analysis 10.9. Country-Level Analysis & Forecast 10.9.1. USA Market Analysis 10.9.1.1. Introduction 10.9.1.2. Market Analysis and Forecast by Market Taxonomy 10.9.1.2.1. By Product 10.9.2. Canada Market Analysis 10.9.2.1. Introduction 10.9.2.2. Market Analysis and Forecast by Market Taxonomy 10.9.2.2.1. By Product 11. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 11.1. Introduction 11.2. Pricing Analysis 11.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 11.4. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 11.4.1. By Country 11.4.1.1. Mexico 11.4.1.2. Brazil 11.4.1.3. Argentina 11.4.1.4. Rest of Latin America 11.4.2. By Product 11.5. Market Attractiveness Analysis 11.5.1. By Country 11.5.2. By Product 11.6. Market Trends 11.7. Key Market Participants - Intensity Mapping 11.8. Drivers and Restraints - Impact Analysis 11.9. Country-Level Analysis & Forecast 11.9.1. Mexico Market Analysis 11.9.1.1. Introduction 11.9.1.2. Market Analysis and Forecast by Market Taxonomy 11.9.1.2.1. By Product 11.9.2. Brazil Market Analysis 11.9.2.1. Introduction 11.9.2.2. Market Analysis and Forecast by Market Taxonomy 11.9.2.2.1. By Product 11.9.3. Argentina Market Analysis 11.9.3.1. Introduction 11.9.3.2. Market Analysis and Forecast by Market Taxonomy 11.9.3.2.1. By Product 12. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 12.4. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 12.4.1. By Country 12.4.1.1. Germany 12.4.1.2. Italy 12.4.1.3. France 12.4.1.4. United Kingdom 12.4.1.5. Spain 12.4.1.6. BENELUX 12.4.1.7. Russia 12.4.1.8. Rest of Europe 12.4.2. By Product 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Product 12.6. Market Trends 12.7. Key Market Participants - Intensity Mapping 12.8. Drivers and Restraints - Impact Analysis 12.9. Country-Level Analysis & Forecast 12.9.1. Germany Market Analysis 12.9.1.1. Introduction 12.9.1.2. Market Analysis and Forecast by Market Taxonomy 12.9.1.2.1. By Product 12.9.2. Italy Market Analysis 12.9.2.1. Introduction 12.9.2.2. Market Analysis and Forecast by Market Taxonomy 12.9.2.2.1. By Product 12.9.3. France Market Analysis 12.9.3.1. Introduction 12.9.3.2. Market Analysis and Forecast by Market Taxonomy 12.9.3.2.1. By Product 12.9.4. UK Market Analysis 12.9.4.1. Introduction 12.9.4.2. Market Analysis and Forecast by Market Taxonomy 12.9.4.2.1. By Product 12.9.5. Spain Market Analysis 12.9.5.1. Introduction 12.9.5.2. Market Analysis and Forecast by Market Taxonomy 12.9.5.2.1. By Product 12.9.6. BENELUX Market Analysis 12.9.6.1. Introduction 12.9.6.2. Market Analysis and Forecast by Market Taxonomy 12.9.6.2.1. By Product 12.9.7. Nordic Countries Market Analysis 12.9.7.1. Introduction 12.9.7.2. Market Analysis and Forecast by Market Taxonomy 12.9.7.2.1. By Product 12.9.8. Russia Market Analysis 12.9.8.1. Introduction 12.9.8.2. Market Analysis and Forecast by Market Taxonomy 12.9.8.2.1. By Product 13. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 13.4. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 13.4.1. By Country 13.4.1.1. China 13.4.1.2. Japan 13.4.1.3. South Korea 13.4.2. By Product 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Product 13.6. Market Trends 13.7. Key Market Participants - Intensity Mapping 13.8. Drivers and Restraints - Impact Analysis 13.9. Country-Level Analysis & Forecast 13.9.1. China Market Analysis 13.9.1.1. Introduction 13.9.1.2. Market Analysis and Forecast by Market Taxonomy 13.9.1.2.1. By Product 13.9.2. Japan Market Analysis 13.9.2.1. Introduction 13.9.2.2. Market Analysis and Forecast by Market Taxonomy 13.9.2.2.1. By Product 13.9.3. South Korea Market Analysis 13.9.3.1. Introduction 13.9.3.2. Market Analysis and Forecast by Market Taxonomy 13.9.3.2.1. By Product 14. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 14.4. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 14.4.1. By Country 14.4.1.1. India 14.4.1.2. Indonesia 14.4.1.3. Malaysia 14.4.1.4. Thailand 14.4.1.5. Philippines 14.4.1.6. Vietnam 14.4.1.7. Rest of South Asia 14.4.2. By Product 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Product 14.6. Market Trends 14.7. Key Market Participants - Intensity Mapping 14.8. Drivers and Restraints - Impact Analysis 14.9. Country-Level Analysis & Forecast 14.9.1. India Market Analysis 14.9.1.1. Introduction 14.9.1.2. Market Analysis and Forecast by Market Taxonomy 14.9.1.2.1. By Product 14.9.2. Indonesia Market Analysis 14.9.2.1. Introduction 14.9.2.2. Market Analysis and Forecast by Market Taxonomy 14.9.2.2.1. By Product 14.9.3. Malaysia Market Analysis 14.9.3.1. Introduction 14.9.3.2. Market Analysis and Forecast by Market Taxonomy 14.9.3.2.1. By Product 14.9.4. Thailand Market Analysis 14.9.4.1. Introduction 14.9.4.2. Market Analysis and Forecast by Market Taxonomy 14.9.4.2.1. By Product 14.9.5. Philippines Market Analysis 14.9.5.1. Introduction 14.9.5.2. Market Analysis and Forecast by Market Taxonomy 14.9.5.2.1. By Product 14.9.6. Vietnam Market Analysis 14.9.6.1. Introduction 14.9.6.2. Market Analysis and Forecast by Market Taxonomy 14.9.6.2.1. By Product 15. Oceania Market 2017 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 15.4. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 15.4.1. By Country 15.4.1.1. Australia 15.4.1.2. New Zealand 15.4.2. By Product 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Product 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country-Level Analysis & Forecast 15.8.1. Australia Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Product 15.8.2. New Zealand Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Product 16. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 16.4. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 16.4.1. By Country 16.4.1.1. GCC Countries 16.4.1.2. Turkey 16.4.1.3. Israel 16.4.1.4. South Africa 16.4.1.5. North Africa 16.4.1.6. Rest of Middle East and Africa 16.4.2. By Product 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Product 16.6. Market Trends 16.7. Key Market Participants - Intensity Mapping 16.8. Drivers and Restraints - Impact Analysis 16.9. Country-Level Analysis & Forecast 16.9.1. GCC Countries Market Analysis 16.9.1.1. Introduction 16.9.1.2. Market Analysis and Forecast by Market Taxonomy 16.9.1.2.1. By Product 16.9.2. Turkey Market Analysis 16.9.2.1. Introduction 16.9.2.2. Market Analysis and Forecast by Market Taxonomy 16.9.2.2.1. By Product 16.9.3. Israel Market Analysis 16.9.3.1. Introduction 16.9.3.2. Market Analysis and Forecast by Market Taxonomy 16.9.3.2.1. By Product 16.9.4. South Africa Market Analysis 16.9.4.1. Introduction 16.9.4.2. Market Analysis and Forecast by Market Taxonomy 16.9.4.2.1. By Product 16.9.5. North Africa Market Analysis 16.9.5.1. Introduction 16.9.5.2. Market Analysis and Forecast by Market Taxonomy 16.9.5.2.1. By Product 17. Market Structure Analysis 17.1. Market Analysis by Tier of Companies 17.2. Market Share Analysis of Top Players 17.3. Market Presence Analysis 17.3.1. By Regional Footprint of Players 17.3.2. Product Footprint of Players 17.3.3. Channel Footprint of Players 18. Competition Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Competition Deep Dive (Tentative List) 18.3.1. Thermo Fisher Scientific Inc. 18.3.1.1. Overview 18.3.1.2. Product Portfolio 18.3.1.3. Key Financials 18.3.1.4. Sales Footprint 18.3.1.5. SWOT Analysis 18.3.1.6. Strategy Overview 18.3.2. Alere Inc., 18.3.2.1. Overview 18.3.2.2. Product Portfolio 18.3.2.3. Key Financials 18.3.2.4. Sales Footprint 18.3.2.5. SWOT Analysis 18.3.2.6. Strategy Overview 18.3.3. Quidel Corporation, 18.3.3.1. Overview 18.3.3.2. Product Portfolio 18.3.3.3. Key Financials 18.3.3.4. Sales Footprint 18.3.3.5. SWOT Analysis 18.3.3.6. Strategy Overview 18.3.4. Becton, Dickinson, and Company, 18.3.4.1. Overview 18.3.4.2. Product Portfolio 18.3.4.3. Key Financials 18.3.4.4. Sales Footprint 18.3.4.5. SWOT Analysis 18.3.4.6. Strategy Overview 18.3.5. Meridian Bioscience, Inc, 18.3.5.1. Overview 18.3.5.2. Product Portfolio 18.3.5.3. Key Financials 18.3.5.4. Sales Footprint 18.3.5.5. SWOT Analysis 18.3.5.6. Strategy Overview 18.3.6. Qiagen N.V., 18.3.6.1. Overview 18.3.6.2. Product Portfolio 18.3.6.3. Key Financials 18.3.6.4. Sales Footprint 18.3.6.5. SWOT Analysis 18.3.6.6. Strategy Overview 18.3.7. bioMérieux SA, 18.3.7.1. Overview 18.3.7.2. Product Portfolio 18.3.7.3. Key Financials 18.3.7.4. Sales Footprint 18.3.7.5. SWOT Analysis 18.3.7.6. Strategy Overview 18.3.8. Bio-Rad Laboratories Inc., 18.3.8.1. Overview 18.3.8.2. Product Portfolio 18.3.8.3. Key Financials 18.3.8.4. Sales Footprint 18.3.8.5. SWOT Analysis 18.3.8.6. Strategy Overview 18.3.9. Cardinal Health Inc., 18.3.9.1. Overview 18.3.9.2. Product Portfolio 18.3.9.3. Key Financials 18.3.9.4. Sales Footprint 18.3.9.5. SWOT Analysis 18.3.9.6. Strategy Overview 18.3.10. Beckman Coulter Inc (Danaher Corporation), 18.3.10.1. Overview 18.3.10.2. Product Portfolio 18.3.10.3. Key Financials 18.3.10.4. Sales Footprint 18.3.10.5. SWOT Analysis 18.3.10.6. Strategy Overview 18.3.11. Hologic Inc., 18.3.11.1. Overview 18.3.11.2. Product Portfolio 18.3.11.3. Key Financials 18.3.11.4. Sales Footprint 18.3.11.5. SWOT Analysis 18.3.11.6. Strategy Overview 18.3.12. La Roche Ltd. 18.3.12.1. Overview 18.3.12.2. Product Portfolio 18.3.12.3. Key Financials 18.3.12.4. Sales Footprint 18.3.12.5. SWOT Analysis 18.3.12.6. Strategy Overview 18.3.13. Abbot Laboratories, 18.3.13.1. Overview 18.3.13.2. Product Portfolio 18.3.13.3. Key Financials 18.3.13.4. Sales Footprint 18.3.13.5. SWOT Analysis 18.3.13.6. Strategy Overview 18.3.14. Quest Diagnostics, 18.3.14.1. Overview 18.3.14.2. Product Portfolio 18.3.14.3. Key Financials 18.3.14.4. Sales Footprint 18.3.14.5. SWOT Analysis 18.3.14.6. Strategy Overview 18.3.15. Luminex Corporation. 18.3.15.1. Overview 18.3.15.2. Product Portfolio 18.3.15.3. Key Financials 18.3.15.4. Sales Footprint 18.3.15.5. SWOT Analysis 18.3.15.6. Strategy Overview 19. Assumptions and Acronyms Used 20. Research Methodology
Healthcare
December 2021
REP-GB-452
September 2023
239 pages
Explore Healthcare Insights
View Reports
Pneumonia Diagnostics Market
